Table 2.
CFQ-R Scales: Change in Score From Baseline to End of Treatment (Days 0 to 28)
| Change From Baseline, Adjusted Mean Score |
|||||
|---|---|---|---|---|---|
| CFQ-R Scales | Placebo | AZLI | Treatment Difference* | 95% CI | p Value |
| Body Image | 1.0 | 3.2 | 2.2 | − 2.2–6.5 | 0.327 |
| Digestion | 1.9 | 2.2 | 0.3 | − 3.5–4.0 | 0.889 |
| Eating | − 4.7 | 3.6 | 8.4 | 4.1–12.7 | < 0.001 |
| Emotional Functioning | − 1.3 | 3.9 | 5.2 | 1.6–8.8 | 0.005 |
| Health Perceptions | − 4.8 | 5.0 | 9.8 | 4.8–14.9 | < 0.001 |
| Physical Functioning | − 6.9 | 2.3 | 9.2 | 3.6–14.8 | 0.001 |
| Respiratory Symptom | − 2.6 | 7.1 | 9.7 | 4.3–15.1 | < 0.001 |
| Role/School | − 4.2 | 2.1 | 6.4 | 1.3–11.4 | 0.014 |
| Social Functioning | − 3.6 | − 1.2 | 2.4 | − 1.7–6.5 | 0.248 |
| Treatment Burden | − 3.1 | 0.2 | 3.2 | − 1.5–7.9 | 0.177 |
| Vitality | − 4.4 | 3.6 | 8.0 | 2.5–13.5 | 0.005 |
| Weight | 1.4 | 4.7 | 3.3 | − 4.0–10.5 | 0.376 |
*Comparison is based on type III sum of squares analysis of covariance models including terms for treatment group and disease severity and CFQ-R baseline score as covariates; difference in treatments is defined as AZLI − placebo.